Millipore Sigma Vibrant Logo

557366 Rosiglitazone - CAS 155141-29-0 - Calbiochem

Overview

Replacement Information

Key Specifications Table

CAS #Empirical Formula
155141-29-0C₁₈H₁₉N₃O₃S.C₄H₄O₄

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
557366-10MG
Retrieving availability...
Limited Availability
Limited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Glass bottle 10 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA thiazolidinedione compound that acts as an anti-diabetic agent and serves as a potent and selective agonist of peroxisome proliferator-activated receptor-g (PPARg) (Kd ~40 nM) in fat cells. Shown to reduce fatty acid uptake and ameliorate lipid metabolism and insulin resistance in animal models of type II diabetes. Reported to activate both a1- and a2-containing AMPK complexes. Unlike troglitazone, it does not induce the activity of P4503A4. Significantly improves the differentiation of C3H10T1/2 stem cells into adipocytes. Shown to block estrogen synthesis by interfering with androgen binding to aromatase, but without affecting aromatase mRNA or protein expression.
      Catalogue Number557366
      Brand Family Calbiochem®
      SynonymsAMPK Signaling Activator X, PPAR Agonist X, PPARγ Agonist IX, 5-[4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione, BRL49653, Avandia
      References
      ReferencesAraki, T., et al. 2011. PPAR Res. 2011, 926438.
      Sozio, M. S., et al. 2011. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G739.
      Gerstein, H., et al. 2006. Drug 368, 9541.
      Mohanty, P., 2004. Journ. Clin. Endocrin. & Metab. 89(6), 2728-2735.
      Fryer, L., et al. 2002. J Biol Chem 277, 25226.
      Goldberg, R., et al. 1999. Drug. 57, 921.
      Young, P., et al. 1998. Journ. Pharm. Exp. Ther. 284, 751.
      Willson, T., et al. 1996. J. Med. Chem.39, 665; Lehmann, J., et al., 1995. JBC 270, 12953.
      Cantello, B., et al., 1994. Bioorg. Med. Chem. Lett. 4, 1181.
      Product Information
      CAS number155141-29-0
      FormWhite powder
      Hill FormulaC₁₈H₁₉N₃O₃S.C₄H₄O₄
      Chemical formulaC₁₈H₁₉N₃O₃S.C₄H₄O₄
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥99% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalog Number GTIN
      557366-10MG 04055977268027

      Documentation

      Rosiglitazone - CAS 155141-29-0 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      Rosiglitazone - CAS 155141-29-0 - Calbiochem Certificates of Analysis

      TitleLot Number
      557366

      References

      Reference overview
      Araki, T., et al. 2011. PPAR Res. 2011, 926438.
      Sozio, M. S., et al. 2011. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G739.
      Gerstein, H., et al. 2006. Drug 368, 9541.
      Mohanty, P., 2004. Journ. Clin. Endocrin. & Metab. 89(6), 2728-2735.
      Fryer, L., et al. 2002. J Biol Chem 277, 25226.
      Goldberg, R., et al. 1999. Drug. 57, 921.
      Young, P., et al. 1998. Journ. Pharm. Exp. Ther. 284, 751.
      Willson, T., et al. 1996. J. Med. Chem.39, 665; Lehmann, J., et al., 1995. JBC 270, 12953.
      Cantello, B., et al., 1994. Bioorg. Med. Chem. Lett. 4, 1181.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision10-August-2012 JSW
      SynonymsAMPK Signaling Activator X, PPAR Agonist X, PPARγ Agonist IX, 5-[4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione, BRL49653, Avandia
      DescriptionA thiazolidinedione compound that acts as an anti-diabetic agent and serves as a potent and selective agonist of peroxisome proliferator-activated receptor-g (PPARg) (Kd ~40 nM) in fat cells. Shown to reduce fatty acid uptake and ameliorate lipid metabolism and insulin resistance in animal models of type II diabetes. Reported to activate both a1- and a2-containing AMPK complexes. Unlike troglitazone, it does not induce the activity of P4503A4. Significantly improves the differentiation of C3H10T1/2 stem cells into adipocytes. Shown to block estrogen synthesis by interfering with androgen binding to aromatase, but without affecting aromatase mRNA or protein expression.
      FormWhite powder
      CAS number155141-29-0
      Chemical formulaC₁₈H₁₉N₃O₃S.C₄H₄O₄
      Structure formulaStructure formula
      Purity≥99% by HPLC
      SolubilityDMSO (100 mg/ml)
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesAraki, T., et al. 2011. PPAR Res. 2011, 926438.
      Sozio, M. S., et al. 2011. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G739.
      Gerstein, H., et al. 2006. Drug 368, 9541.
      Mohanty, P., 2004. Journ. Clin. Endocrin. & Metab. 89(6), 2728-2735.
      Fryer, L., et al. 2002. J Biol Chem 277, 25226.
      Goldberg, R., et al. 1999. Drug. 57, 921.
      Young, P., et al. 1998. Journ. Pharm. Exp. Ther. 284, 751.
      Willson, T., et al. 1996. J. Med. Chem.39, 665; Lehmann, J., et al., 1995. JBC 270, 12953.
      Cantello, B., et al., 1994. Bioorg. Med. Chem. Lett. 4, 1181.